Adherence as a particular issue with protease inhibitors

Journal of the Association of Nurses in AIDS Care

Volumn 8, Issue SUPPL., 1997, Pages 10-17

  Katzenstein, David A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral resistance; Mutation; Protease inhibitor

Indexed keywords

PROTEINASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; DRUG EFFECT; HUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DRUG RESISTANCE, MICROBIAL; GUIDELINE ADHERENCE; HIV PROTEASE INHIBITORS; HUMANS; PATIENT COMPLIANCE; PRACTICE GUIDELINES; RNA, VIRAL;

EID: 0030630234     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3290(97)80003-9     Document Type: Article

References (2)

1. Agouron Pharmaceuticals. (1996). Viracept (nelfinavir) complete prescribing information. La Jolla, CA: Author.
2. Centers for Disease Control. (1996). Update: Mortality attributable to HIV infection among persons aged 25-44 years-United States 1994. Morbidity and Mortality Weekly Report, 45.